Solution for injections Emaveyl is shown for treatment of the symptomatic anemia connected with chronic kidney disease.

Structure

Active ingredient: epoetin alpha;

1 ml of erythropoietin of the person recombinant 2000 ME, 3000 ME, 4000 ME, 10000 ME.

Excipients: human seralbumin, sodium chloride, sodium citrate, citric acid monohydrate, water for injections.

to Patients at whom the true erythrocyte aplasia (PRCA) owing to treatment by erythropoietin develops the medicament Emaveyl or any other erythropoietin is contraindicated to

Contraindication

Uncontrollable hypertensia.

needs to take into account all contraindications connected with the program of selection of autologous blood among the patients receiving epoetin an alpha.

Hypersensitivity to medicament components.

to Patients, subjects elective orthopedic surgery, but did not participate in the program of selection of autologous blood, use of an epoetin an alpha contraindicated at heavy coronary, peripheral and arterial, carotid or cerebral vascular diseases and also at recently had myocardial infarction or a stroke.

use Is contraindicated to surgical patients who through any reasons cannot perform adequate antitrombotichesky prevention.

Route of administration

Epoetin an alpha can be applied by subcutaneous and intravenous injections.

As well as at use of any parenteral medicines, medicament epoetin an alpha before use is checked for lack of visible foreign particles and discoloration of solution.

Bottle: the sterile needle is connected to the sterile syringe and gain necessary amount of the medicament Emaveyl in the syringe for intravenous or hypodermic administration.

Previously filled syringe: open external packing, remove a rubber cap for protection of a needle, carry out or a subcutaneous injection.

Feature of use

Pregnant

Can be applied during pregnancy only in cases when the potential advantage of therapy exceeds potential risk for a fruit.

by

.

Drivers

does not influence.

Overdose

Drug has broad therapeutic action. At overdose of an epoetin an alpha there are effects reflecting high extent of manifestation of pharmacological effect of hormone. At exclusively high levels of hemoglobin performing phlebotomy is possible. Symptomatic therapy is in case of need performed.

Side effects

Most frequent undesirable side reaction at treatment of an epoetin an alpha oncological patients and patients with chronic kidney disease had a dose-dependent increase in pressure or strengthening of the available hypertensia. Control of arterial blood pressure needs to be carried out almost from an initiation of treatment. Deep venous thrombosis, a pulmonary embolism, spasms, diarrhea, nausea, a headache, grippopodobny a state, a pyrexia, rash and vomiting were other frequent side reactions which were observed in clinical trials.

Interaction

Is not present any data which would indicate that treatment of an epoetin the alpha influences metabolism of other drugs. However, as medicaments of cyclosporine contact erythrocytes, there is a probability of medicamentous interaction. At simultaneous use of Emaveyl and cyclosporine it is necessary to control the level of the last in blood and, if necessary, to adjust a dose.

to Store

at a temperature from 2 °C to 8 °C in original packing. It is necessary to observe the mode of a cold chain during medicament use. Not to stir up but not to freeze. To store out of children's reach.

Syringes which will apply or which can be used have to be stored by

at the room temperature (not above 25 °C) during the maximum single term of 7 days.

Expiration date - 2 years.